Neuman RI, van der Meer MMA, Saleh L, et al. - Given a possible contribution of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) in the pathogenesis of preeclampsia, researchers sought to estimate their role as biomarkers and determine if they associate with angiogenic markers and/or clinical manifestations of preeclampsia. Their surrogates C-terminal pro-AVP (Copeptin) and mid-regional pro-ANP (MR-proANP) were measured via performing a retrospective analysis of a prospective cohort study including 526 women with suspected or confirmed preeclampsia, originally intended to evaluate the use of soluble Fms-like tyrosine kinase-1/Placental growth factor (sFlt-1/PlGF) ratio. Outcomes suggested a limited value of copeptin and MR-proANP for predicting preeclampsia-related complications when compared with the sFlt-1/PlGF ratio. However, the data indicate the possible contribution of both copeptin and MR-proANP to the occurrence of proteinuria, with copeptin exerting this effect independently of sFlt-1/PlGF ratio.